Video Series

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.

Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Panelist discusses how HS Centers of Excellence integrating multidisciplinary care, personalized treatments, comprehensive tracking, and holistic patient support strategies can significantly improve HS patient outcomes through coordinated, comprehensive care approaches.

Panelists discuss how increasing insurance step edit requirements for high-dose IV iron formulations have created barriers to optimal patient care, requiring providers to implement strategic prior authorization processes and develop documentation protocols to demonstrate medical necessity while advocating for appropriate patient access to these medications.

Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and administering IV iron treatments, leading clinicians to favor products that can achieve iron repletion in fewer sessions.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.

Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.

Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

Panelist discusses how HS Centers of Excellence demonstrate potential for enhanced health care delivery through coordinated, specialized care approaches, with managed care organizations driving adoption through strategic incentives and collaborative frameworks.

Panelists discuss key gaps in communication between academic and community centers regarding the use of bispecifics and strategies to bridge them as well as best practices for ensuring a smooth transition of care when patients move between settings.

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.

Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.

Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.

Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making.

Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions.

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on how prior therapy exposure influences the choice of subsequent treatments.

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors influencing the decision to administer these agents at an academic center vs a community setting.

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

Panelist discusses how Centers of Excellence for hidradenitis suppurativa (HS) differentiate through comprehensive, patient-centered multidisciplinary care models integrating specialized dermatologic, surgical, psychological, and pain management interventions to holistically address complex chronic conditions while navigating systemic health care implementation challenges.

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy considerations, with decisions between discontinuation vs switching to alternative BTK inhibitor (BTKi) therapy being influenced by factors such as depth and duration of response, toxicity severity, patient preferences regarding adverse effects and treatment schedules, and quality-of-life considerations.

Panelists discuss best practices for successfully implementing a bispecifics program and overcoming logistical challenges.

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic complications such as osteomalacia and metabolic disturbances, potentially impacting patients’ mobility, energy levels, and overall quality of life if not properly monitored and managed.

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility requirements for administration, while emphasizing that modern formulations have significantly improved safety profiles compared with older products.